TetraLogic Pharmaceuticals Report issue

For profit Phase 1 Phase 2
Founded: Malvern PA United States (2001)
Status: Acquired by Medivir (2016)

Organization Overview

First Clinical Trial
2009
NCT00993239
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Alopecia (Phase 2)

Alopecia Areata (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 2)

Cystadenocarcinoma, Serous (Phase 2)

Fallopian Tube Neoplasms (Phase 1)

Hepatitis (Phase 1)

Hepatitis A (Phase 1)

Hepatitis B (Phase 1)

Hepatitis B, Chronic (Phase 1)

Leukemia (Phase 2)

Leukemia, Myelomonocytic, Acute (Phase 2)

Leukemia, Myelomonocytic, Chronic (Phase 2)

Leukemia, Myelomonocytic, Juvenile (Phase 2)

Lymphoma (Phase 2)

Lymphoma, T-Cell (Phase 2)

Lymphoma, T-Cell, Cutaneous (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Neoplasms (Phase 2)

Ovarian Neoplasms (Phase 2)

Preleukemia (Phase 2)

Psoriasis (Phase 1)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 13
  • # of Trial APIs: 12